

Remarks

Claims 42-48, 52-56, 59, 62-66, 69 and 72-74 are pending in the instant application on entry of the present amendment. As agreed in the telephone interview with the Examiner on August 11, 2003, claim 42(f) has been amended to recite "excluding the signal sequence," and to remove the recitation of "expressed by a recombinant cell" and "wherein said amino acid sequence is encoded by the cDNA plasmid contained in ATCC Deposit No. 75927." Support for the amended claim is found throughout the specification as originally filed and in the claims pending in the instant application prior to entry of the present amendment. Accordingly, no new matter has been added to the claims.

Applicants respectfully request that the amendments and remarks of the present response be entered and made of record in the present application.

I Rejections Under 35 U.S.C. § 112, second paragraph

A. The Examiner has maintained the rejection of independent claim 42 as well as claims 48, 52, 53 and 54, which depend therefrom, under 35 U.S.C. § 112, second paragraph, as allegedly being "indefinite because they recite the term 'a polypeptide having the amino acid sequence expressed by a recombinant cell'." See, Paper No. 33, page 2.

The Examiner's attention is respectfully directed to presently amended claim 42, as well as claims 48, 52, 53 and 54, which have been amended herein in light of the telephone conference on August 11, 2003. Applicants believe that the present amendment addresses the Examiner's concerns and that the metes and bounds of the claims are clear.


Accordingly, Applicants respectfully request that the present rejection of claims 42, 48, and 52-54 under 35 U.S.C. § 112, second paragraph, be reconsidered and withdrawn.

Conclusion

Applicants respectfully request that the amendment and remarks of the present response be entered and made of record in the present application. The present application is believed to be in condition for allowance. Early notice to that effect is earnestly solicited. If, in the opinion of the Examiner, a telephone conference would expedite prosecution, the undersigned can be reached at the telephone number indicated below. If a fee is required in connection with this paper, please charge Deposit Account No. 08-3425 for the appropriate amount.

Respectfully submitted,

Dated: August 12, 2003



Lin J. Hymel (Reg. No. 45,414)
Attorney for Applicants
Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (phone)

Enclosures
KKH/LJH/BM/lcc

Appl'n Serial No.: 09/246,129

7

PF141P4

PTO/SB/97 (05-03)

Approved for use through 04/30/2003 OMB 0651-0031

U. S. Patent and Trademark Office, U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 09/246,129

Attorney Docket No.: PF141P4

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on August 12, 2003
Date



Signature

Lin J. Hymel

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Fee Transmittal Sheet;

Amendment With Response Under 37 C.F.R. §1.116 to Paper No. 28; and
Certificate of Transmission Under 37 C.F.R. §1.8.

PTO/SB/97 (12-97)

Approved for use through 9/30/00 OMB 0651-0031

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Certificate of Transmission Under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on October 2, 2003
Date


Signature

Lin J. Hymel
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Fee Transmittal (1 page),
Communication,
Copy of Amendment with Response Under 37 C.F.R. 1.116 as filed by fax on August 12, 2003;
Copy of the Certificate of Transmission under 37 C.F.R. 1.8 as transmitted on August 12, 2003;
Copy of the Fee Transmittal Sheet as transmitted on August 12, 2003;
Copy of the Fax Transmission Cover sheet as transmitted on August 12, 2003,
Copy of the Auto-Reply Facsimile Transmission demonstrating receipt by the USPTO of Applicants fax transmission of August 12, 2003; and
Certificate of Transmission under 37 CFR 1.8 (1 page)